Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies

Roszmann, Anna; Podlewska, Aleksandra; Lau, Yue Hui; Boura, Iro; Hand, Annette

doi:10.1016/bs.irn.2022.04.005

Cited by 5 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD patients are particularly recommended to use vaccination as a basic protection against SARS-CoV-2 infection [ 104 ], and the Movement Disorder Society has released a COVID-19 vaccine statement to address aspects of the COVID-19 vaccination among patients [ 105 ]. Approved mRNA-based vaccines and vector vaccines under development induce immunization through mechanisms that do not interact with the neurodegenerative process of PD.…”

Section: Discussionmentioning

confidence: 99%

Parkinson’s Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?

et al. 2023

View full text Add to dashboard Cite

The literature has long established the association between aging and frailty, with emerging evidence pointing to a relationship between frailty and SARS-CoV-2 contagion. The possible neurological consequences of SARS-CoV-2 infection, associated with physical and cognitive frailty, could lead to a worsening of Parkinson’s disease (PD) in infected patients or—more rarely—to an increase in the Parkinsonian symptomatology. A possible link between those clinical pictures could be identified in vitamin D deficiency, while the whole process would appear to be associated with alterations in the microbiota–intestine–brain axis that fall within the α-Synuclein Origin site and Connectome (SOC) model, and allow for the identification of a body-first PD and a brain-first PD. The model of care for this condition must consider intrinsic and extrinsic variables so that care by a multidisciplinary team can be successfully predicted. A multidimensional screening protocol specifically designed to identify people at risk or in the early stages of the disease should begin with the investigation of indices of frailty and microbiota–intestine–brain axis alterations, with a new focus on cases of hypovitaminosis D.

show abstract

Section: Discussionmentioning

confidence: 99%

Parkinson’s Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…There is a strong recommendation for PD patients to be vaccinated against COVID-19 unless specific contraindications exist [ 69 ]. COVID-19 vaccines are not expected to alter the effect of anti-parkinsonian medication, while their benefits and risks are believed to be the same for PD patients and their age-matched counterparts [ 70 ].…”

Section: What Effect If Any Does Covid-19 Vaccination Have On People ...mentioning

confidence: 99%

SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now

Boura,

Qamar,

Daddoveri

et al. 2023

Biomedicines

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has been discussed in the context of Parkinson’s disease (PD) over the last three years. Now that we are entering the long-term phase of this pandemic, we are intrigued to look back and see how and why the community of patients with PD was impacted and what knowledge we have collected so far. The relationship between COVID-19 and PD is likely multifactorial in nature. Similar to other systemic infections, a probable worsening of PD symptoms secondary to COVID-19, either transient or persistent (long COVID), has been demonstrated, while the COVID-19-related mortality of PD patients may be increased compared to the general population. These observations could be attributed to direct or indirect damage from SARS-CoV-2 in the central nervous system (CNS) or could result from general infection-related parameters (e.g., hospitalization or drugs) and the sequelae of the COVID-19 pandemic (e.g., quarantine). A growing number of cases of new-onset parkinsonism or PD following SARS-CoV-2 infection have been reported, either closely (post-infectious) or remotely (para-infectious) after a COVID-19 diagnosis, although such a link remains hypothetical. The pathophysiological substrate of these phenomena remains elusive; however, research studies, particularly pathology studies, have suggested various COVID-19-induced degenerative changes with potential associations with PD/parkinsonism. We review the literature to date for answers considering the relationship between SARS-CoV-2 infection and PD/parkinsonism, examining pathophysiology, clinical manifestations, vaccination, and future directions.

show abstract

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study

et al. 2023

View full text Add to dashboard Cite

Continuous subcutaneous apomorphine infusion (CSAI) is used to treat patients with Parkinson’s disease (PD) who are experiencing motor fluctuations. However, the need to initiate this treatment during a hospital stay may restrict patients’ access to it. To assess the feasibility and benefits of initiating CSAI in the patient’s own home. A French prospective multicenter longitudinal observational study (APOKADO) among patients with PD who required subcutaneous apomorphine, comparing in-hospital versus home initiation. Clinical status was assessed according to the Hoehn and Yahr score), the Unified Parkinson’s Disease Rating Scale Part III, and the Montreal Cognitive Assessment. We assessed patients’ quality of life with the 8-item Parkinson’s Disease Questionnaire, rated the improvement in their clinical status on the 7-point Clinical Global Impression–Improvement scale, recorded adverse events, and ran a cost–benefit analysis. 145 patients with motor fluctuations were included in 29 centers (office and hospital). Of these, 106 (74%) were initiated onto CSAI at home, and 38 (26%) in hospital. At inclusion, the two groups were comparable for all demographic and PD characteristics. After 6 months, quality of life, adverse events and early dropout rates were similarly rare-across the two groups. Patients in the home group improved more quickly their quality of life and became more autonomous in managing the device than those in the hospital group, and their care costed less. This study shows that home (versus in-hospital) initiation of CSAI is feasible, improves patients’ quality of life more quickly, with the same level of tolerance. It is also less expensive. This finding should make it easier for patients to access this treatment in the future.

show abstract

Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies

Cited by 5 publications

References 65 publications

Parkinson’s Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?

Parkinson’s Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?

SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study

Contact Info

Product

Resources

About